Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 14, 2008

View Archived Issues

Paclitaxel plus bevacizumab combination active in metastatic breast cancer

Pfizer's pan-ERBB inhibitor shows preclinical efficacy in gefitinib-resistant lung cancer

Somaxon completes 26-week transgenic mouse carcinogenicity study of Silenor

Lung and renal improvement with sirolimus in tuberous sclerosis complex and LAM / News in Context

Arcion raises funds in Series A financing to help develop ARC-4558 for pain

Anthera obtains rights from Amgen for AMG-623 for systemic lupus erythematosus

Celltrion and CSL sign agreement for CSL-360 for acute myeloid leukemia

Arena's APD-791 for arterial thrombosis well tolerated in phase Ia clinical trial

Update on Cipher's appeals of approvable letters for CIP-isotretinoin and CIP-tramadol

Novacea scales back clinical development of anticancer prodrug banoxantrone

Amarin to initiate phase IIa trial of AMR-101 for age-associated memory impairment

FDA grants expanded indication for general hemostasis in surgery for Omrix's Evicel

FDA accepts for filing BioDelivery Sciences' NDA for BEMA Fentanyl for cancer pain

New compounds for hypertension and other cardiovascular disorders described

Recent patents describe novel agents for neurological disorders

Celtic Pharma and Inspiration sign agreement for development of Factor IX for hemophilia B

Hammersmith Imanet patents novel diagnostic agents

Positive preclinical results with Abbott's new DGAT-1 inhibitor reported

Transgene reports positive preliminary data from phase IIb of TG-4010 for advanced NSCLC

FDA and Ardana reach agreement on clinical development of teverelix LA for endometriosis

FDA Anti-infective Drug Advisory Committee grants review for Basilea's ceftobiprole

FDA grants orphan drug designation to Curacyte's hemoximer for cardiogenic shock

ImmuPharma gains rights to nucleolin antagonist IPP-204106 for cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...